Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > halflife : 1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"' or ~12 hours or ~25 days

Use the filters below to narrow your results.

generic:
None (2) · Duloxetine (1) · Furosemide (1)
brand:
Aduhelm (1) · Belsomra (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Lasix (1)
classes:
Anti-amyloid beta (Aβ) monoclonal antibody (1) · Antidepressant (1) · Anxiolytic (1) · Dual orexin receptor antagonist (DORA) (1) · SNRI (1) · the first approved (1) · [[:Category:Diuretics|Diuretic]] (1) · [[:Category:Loop_diuretics|Loop diuretic]] (1)
mechanism:
None (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1)
uses:
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · '"`UNIQ--vote-0000021C-QINU`"', '"`UNIQ--vote-0000021D-QINU`"', '"`UNIQ--vote-0000021E-QINU`"', '"`UNIQ--vote-0000021F-QINU`"', '"`UNIQ--vote-00000220-QINU`"', '"`UNIQ--vote-00000221-QINU`"' (1)
starting dose:
None (1) · 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 20-40 mg PO/IV; titrate by clinical response. In diuretic-resistant heart failure or CKD, doses to 200 mg or higher may be needed (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)
preparations:
None (1) · 20, 40, 80 mg tablets; 10 mg/mL oral solution; 10 mg/mL IV (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)
fda max:
None (1) · 20 mg/d (1) · 600 mg/d typical practical ceiling in heart failure (1) · Withdrawn 2024 (1)
routes:
IM (1) · IV (1) · IV infusion every 4 weeks (1) · Oral (3)
onset:
IV: 5 minutes; PO: 30-60 minutes (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · PET Aβ reduction over months (1) · ~30 min (1)
duration:
Chronic daily dosing (1) · IV: ~2 hours; PO: 6-8 hours (1) · Withdrawn (1) · ~7-8 hours (1)
halflife: (Click arrow to add another value)
bioavailability:
100% (IV) (1) · ~50% (highly variable) (1) · ~50% (oral; highly variable, 10-100%, hence the standard 1:2 IV-to-PO conversion)'"`UNIQ--ref-00000223-QINU`"' (1) · ~82% (1)
pregnancy:
Avoid where possible; can reduce uteroplacental perfusion and produce neonatal electrolyte disturbance. Reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Category C (1) · Discontinued/withdrawn (1) · Limited data; avoid (1)
legal:
Rx, Schedule IV (US) (1) · Rx-only (1) · Withdrawn from US market January 2024 (1) · [[USLegal:Prescription only|Rx-only]] in US (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.

There are no results for this report.

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"